SciSparc Ltd. (Nasdaq: SPRC) starts Phase IIb SCI-110 trial for Tourette

Rhea-AI Filing Summary

SciSparc Ltd., through its majority-owned subsidiary NeuroThera Labs, reported the initiation of a Phase IIb clinical trial site at Hannover Medical School in Germany for SCI-110, a proprietary cannabinoid-based treatment candidate for adult Tourette Syndrome.

The randomized, double-blind, placebo-controlled, cross-over study will evaluate daily oral SCI-110 in patients aged 18-65, with primary endpoints based on changes in tic severity on the Yale Global Tic Severity Scale at weeks 12 and 26 versus baseline. The multicenter trial also includes the Yale Child Study Center in Connecticut and Tel Aviv Sourasky Medical Center in Israel, building on prior Phase IIa data that showed an average tic reduction of 21%.

Key Figures

Phase IIa tic reduction: 21% Patient age range: 18-65 years Primary endpoint timing: Weeks 12 and 26 +2 more

5 metrics

Phase IIa tic reduction 21% Average tic reduction across all participants in the prior Phase IIa study

Patient age range 18-65 years Eligibility range for participants in the Phase IIb SCI-110 trial

Primary endpoint timing Weeks 12 and 26 Yale Global Tic Severity Scale assessments versus baseline in Phase IIb

Clinical trial phase Phase IIb Current development stage of SCI-110 for adult Tourette Syndrome

Contact phone +972-3-6167055 Investor relations telephone number provided for SciSparc

Key Terms

Phase IIb clinical trial, Tourette Syndrome, Yale Global Tic Severity Scale, double-blind, placebo-controlled, cross-over trial, +1 more

5 terms

Phase IIb clinical trial medical

"announced the initiation of its Phase IIb clinical trial site"

A Phase IIb clinical trial is a mid-stage study that tests whether a drug works at one or more specific doses in the patients it intends to treat, while continuing to monitor safety. Think of it as a dress rehearsal that aims to prove the treatment actually delivers the benefit seen in early tests before a large, expensive final trial. For investors, positive Phase IIb results significantly reduce scientific risk and can lift a drug’s commercial and valuation prospects, while failures often trigger sharp reassessments.

Tourette Syndrome medical

"treatment candidate for Tourette Syndrome (TS) in adults"

Tourette syndrome is a neurological condition that causes repeated, involuntary movements or sounds known as tics, which typically begin in childhood and vary widely in severity. Investors pay attention because it creates a defined need for medical treatments, therapies, and support services—similar to how recurring software bugs create demand for updates—affecting market size, regulatory scrutiny, clinical trial opportunities and potential workforce or cost implications for healthcare and education sectors.

Yale Global Tic Severity Scale medical

"measured by the gold standard, Yale Global Tic Severity Scale"

A clinician-rated questionnaire that measures the severity and impact of motor and vocal tics, including number, frequency, intensity, complexity and overall impairment. Think of it like a standardized report card for tics used in clinical care and drug trials; it matters to investors because scores are commonly used as an objective endpoint in research and regulatory filings, which can influence trial outcomes, approval prospects and commercial value of treatments.

double-blind, placebo-controlled, cross-over trial medical

"study is a randomized, double-blind, placebo-controlled, cross-over trial"

palmitoylethanolamide medical

"combines dronabinol with the endocannabinoid-like palmitoylethanolamide"

Palmitoylethanolamide (PEA) is a naturally occurring fatty molecule produced in the body and sold as a supplement or experimental therapy for reducing pain and inflammation; think of it as a built‑in calming signal that helps quiet irritated tissues. Investors watch PEA because its potential medical benefits, regulatory path (supplement vs. drug), and clinical evidence drive market demand, pricing and the risk/reward of companies developing or selling PEA-based products — similar to how a promising ingredient can change the fortunes of a consumer brand.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/15/2026 - 04:02 PM Accepted by SEC EDGAR 07/15/2026 - 04:01 PM Learn about SEC filing dates

FAQ

What did SciSparc (SPRC) announce regarding its Tourette Syndrome program?

SciSparc announced that subsidiary NeuroThera Labs has initiated a Phase IIb clinical trial site at Hannover Medical School in Germany for SCI-110, its cannabinoid-based treatment candidate for adult Tourette Syndrome, as part of a multicenter global study.

What is SCI-110 in SciSparc (SPRC)’s pipeline?

SCI-110 is a proprietary combination of dronabinol and the endocannabinoid-like compound palmitoylethanolamide, formulated in a single dosage form to reduce tics and comorbid symptoms in adults with Tourette Syndrome while aiming to minimize side effects in clinical use.

How is the Phase IIb SCI-110 trial for SciSparc (SPRC) designed?

The Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial in patients aged 18-65, assessing daily oral SCI-110 with primary endpoints based on tic severity scores at weeks 12 and 26 compared with baseline values.

What prior clinical results support SciSparc (SPRC)’s SCI-110 program?

A preceding Phase IIa study of SCI-110 showed an average tic reduction of 21% across all participants, measured by the Yale Global Tic Severity Scale Total Tic Score, providing the basis for advancing to the larger, controlled Phase IIb trial.

Where will SciSparc (SPRC)’s Phase IIb SCI-110 trial be conducted?

The Phase IIb trial will run at Hannover Medical School in Germany, the Yale Child Study Center in New Haven, Connecticut, and Tel Aviv Sourasky Medical Center in Israel, reflecting a multicenter, international clinical development strategy.

What other development programs does SciSparc (SPRC) pursue?

SciSparc, through NeuroThera, is developing SCI-110 for Tourette syndrome and Alzheimer’s disease with agitation, and SCI-210 for Autism Spectrum Disorder and status epilepticus, alongside a business focused on hemp seed oil-based products sold on Amazon.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of July 2026

Commission File Number: 001-38041

SCISPARC LTD.

(Translation of registrant’s name into English)

20 Raul Wallenberg Street, Tower A,

Tel Aviv 6971916 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒     Form 40-F ☐

CONTENTS

On July 15, 2026, SciSparc Ltd. (the “Company”) issued a press release titled “SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome.” A copy of this press release is furnished herewith as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K and is incorporated by reference herein.

The first four paragraphs and the section titled “Forward-Looking Statements” in the press release are incorporated by reference into the Company’s registration statements on Form F-3 (File Nos. 333-286099, 333-275305, 333-269839, 333-266047, 333-248670, 333-255408, 333-293167 and 333-293533) and on Form S-8 (File Nos. 333-278437, 333-225773, 333-286791 and 333-292952) filed with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

1

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press release issued by SciSparc Ltd. titled “SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome.”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SCISPARC LTD.
	By:	/s/ Oz Adler
	Name:	Oz Adler
	Title:	Chief Executive Officer and Chief Financial Officer

Date: July 15, 2026

3

Exhibit 99.1

 

SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

TEL AVIV, Israel, July 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the initiation of its Phase IIb clinical trial site at Hannover Medical School, Hanover, Germany (“MHH”), for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome (TS) in adults.

The trial, which previously received regulatory clearance from Germany’s Federal Institute for Drugs and Medical Devices and MHH’s ethics committee, is now advancing towards the next stage at Hannover Medical School, one of the key clinical sites of the study. SCI-110 combines dronabinol with the endocannabinoid-like palmitoylethanolamide in an innovative one dosage form designed to reduce tics and comorbid symptoms in adults with TS while minimizing side effects.

In addition to Hannover Medical School, the trial will be conducted at Yale Child Study Center in New Haven, Connecticut, and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel.

Building on the positive safety and efficacy results from the Phase IIa study, which showed an average tic reduction of 21% across the entire participants sample, as measured by the gold standard, Yale Global Tic Severity Scale Total Tic Score scale, the Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial designed to evaluate the efficacy, safety, and tolerability of daily oral SCI-110. Patients aged 18-65 will be randomized to receive either SCI-110 or placebo, with the primary efficacy endpoint being the change in tic severity measured by the Yale Global Tic Severity Scale at weeks 12 and 26 compared to the baseline. Safety will be assessed through monitoring of adverse events.

Dr. Adi Zuloff-Shani, Chief Technology Officer of NeuroThera Labs, commented: “The initiation of the German site marks an important step forward in our global development program for SCI-110. Tourette Syndrome is an unmet medical need condition with limited treatment options, particularly in adults who experience persistent, severe, and debilitating symptoms. We believe SCI-110 has the potential to offer a novel, more effective and safer alternative. We are committed to advancing this promising therapy and delivering meaningful data to support its future approval.”

About SciSparc Ltd. (Nasdaq: SPRC):

The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI- 210 for the treatment of Autism Spectrum Disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

About NeuroThera Labs Inc.

NeuroThera Labs Inc. (TSXV: NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the conduct, progress and expected timing of NeuroThera’s Phase IIb clinical trial of SCI-110 for the treatment of TS; the anticipated participation of additional clinical trial sites, including the Yale Child Study Center and the Tel Aviv Sourasky Medical Center; patient enrollment and randomization; the evaluation of the efficacy, safety and tolerability of SCI-110; the potential of SCI-110 to offer a novel or safer alternative to existing treatments; the generation of data to support future regulatory approval; and the continued development and potential commercialization of SCI-110. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:

IR@scisparc.com
Tel: +972-3-6167055

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: NEUROTHERA LABS ANNOUNCE 10.1 KB